| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy. flippi@endoc.med.unipi.it
OBJECTIVE: This study tested the hypothesis that administration of human recombinant thyroid-stimulating hormone (rhTSH: Thyrogen, thyrotropin alpha) could promote iodine-131 ((131)I) uptake in the therapy for metastatic or locally invasive differentiated thyroid cancer (DTC), obviating L-thyroxine suppressive therapy (L-T4) withdrawal and hypothyroidism in patients with advanced disease. METHODS: Twelve totally (or almost completely) thyroidectomized adults, nine of whom had received earlier therapy after L-T4 withdrawal, underwent (131)I treatment while euthyroid on L-T4, after rhTSH administration. Nine underwent diagnostic whole-body scanning (WBS) after two consecutive daily i.m. injections (0.9 mg) of rhTSH. They then received an identical second course of rhTSH to promote therapeutic (131)I uptake. Post-therapy WBS was performed one week later. Three patients received only rhTSH (131)I therapy. RESULTS: Administration of rhTSH promoted (131)I uptake in all patients, as demonstrated by post-therapy WBS. Administration of rhTSH also promoted a significant increase in serum thyroglobulin (Tg) concentrations. According to the most recent measurements, 3-12 months after therapy, serum Tg levels fell in four, and stabilized in two out of eleven patients. Upon additional rhTSH-WBS 8 months post-study, a reduction in one metastatic site was noted in one patient. The rhTSH was well tolerated, with mild, transient fever and/or nausea occurring in only a minority of patients. Individuals with bone metastases experienced degrees of peritumoral pain and swelling that were similar (though more short-lived) to those seen in the same or other patients after L-T4 withdrawal. CONCLUSIONS: Administration of rhTSH is a safe, successful tool for inducing (131)I uptake in local and metastatic DTC lesions, and avoids L-T4 withdrawal, preserving metabolic homeostasis and preventing the debilitating effects of hypothyroidism.
This article has been cited by other articles:
|
|
 |
|
  M. G. Castagna, A. Pinchera, A. Marsili, M. Giannetti, E. Molinaro, P. Fierabracci, L. Grasso, F. Pacini, F. Santini, and R. Elisei Influence of Human Body Composition on Serum Peak Thyrotropin (TSH) after Recombinant Human TSH Administration in Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4047 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, and F. Pacini rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr. Relat. Cancer, March 1, 2005; 12(1): 49 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. de Keizer, A. Hoekstra, M. W. Konijnenberg, F. de Vos, B. Lambert, P. P. van Rijk, C. J.M. Lips, and J. M.H. de Klerk Bone Marrow Dosimetry and Safety of High 131I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer J. Nucl. Med., September 1, 2004; 45(9): 1549 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Nielsen, S. J. Bonnema, and L. Hegedus Effects of 0.9 mg Recombinant Human Thyrotropin on Thyroid Size and Function in Normal Subjects: A Randomized, Double-Blind, Cross-Over Trial J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2242 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Driedger and N. Kotowycz Two Cases of Thyroid Carcinoma That Were Not Stimulated by Recombinant Human Thyrotropin J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 585 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Menzel, W. T. Kranert, N. Dobert, M. Diehl, T. Fietz, N. Hamscho, U. Berner, and F. Grunwald rhTSH Stimulation Before Radioiodine Therapy in Thyroid Cancer Reduces the Effective Half-Life of 131I J. Nucl. Med., July 1, 2003; 44(7): 1065 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Robbins and K. S. Pentlow Coming of Age: Recombinant Human Thyroid-Stimulating Hormone as a Preparation for 131I Therapy in Thyroid Cancer J. Nucl. Med., July 1, 2003; 44(7): 1069 - 1071. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Robbins and A. K. Robbins Recombinant Human Thyrotropin and Thyroid Cancer Management J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1933 - 1938. [Full Text] [PDF]
|
|
|
|
|
|
G. Vitale, G. A. Lupoli, A. Ciccarelli, A. Lucariello, M. R. Fittipaldi, F. Fonderico, A. Panico, and G. Lupoli Influence of Body Surface Area on Serum Peak Thyrotropin (TSH) Levels after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1319 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Muller, K. H. Bohuslavizki, S. Klutmann, and M. Clausen Value of Recombinant Human Thyrotropin in High-Dose Radioiodine Therapy: A Case Report J. Nucl. Med. Technol., December 1, 2002; 30(4): 185 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pacini, E. Molinaro, M. G. Castagna, F. Lippi, C. Ceccarelli, L. Agate, R. Elisei, and A. Pinchera Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4063 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Braga, M. D. Ringel, and D. S. Cooper Sudden Enlargement of Local Recurrent Thyroid Tumor after Recombinant Human TSH Administration J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5148 - 5151. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
